

Peer Review File

Article information: <https://dx.doi.org/10.21037/tlcr-22-883>

Reviewer A

Dr. Schenk reported her work entitled "narrative review: immunotherapy in ALK+ lung cancer: current status and future direction" which is comprehensive review. I have the following comments:

Comment 1: Language revision is essential.

Please replace "the immune system interfaces with ALK+ NSCLC and this interaction" to be "the immune system interacts with ALK+ NSCLC and this interaction".

Reply 1: I thank the reviewer for their time and comments on the manuscript. Language changed as recommended in the abstract (Line 18).

Comment 2: Please replace "Key Content and Findings" into "Results" and try to specify the total number of obtained/reviewed papers from your research. If possible, please to add PRISMA flowchart to your work (Optional request).

Reply 2: "Key Content and Findings" was used based on the guidance provided by the updated journal template for Narrative Reviews.

As per the journal template, "Table 1 The Search Strategy Summary" was included in the manuscript. This has now been expanded to include the search strategy for PubMed (Table 1) and the search strategy for ClinicalTrials.gov (Table 2). A methods section has now been added in accordance with the journal's instruction (lines 57-65).

I am unable to specify the number of obtained/reviewed papers from my literature review as per the journal requirements, while a narrative review is comprehensive, it does not require the same methodological rigor as a systematic review.

Per the journal's instructions:

*"Note: please note that a narrative review is less methodologically demanding than a systematic review, as it does not require a search of all literature in a field. Therefore, the search strategy summary of a narrative review is mainly used for more transparent reporting."*

Comment 3: Please try to expand more in your abstract instead of writing "discussed" in this sentence "TKI mediated tumor cell clearance are discussed as future immunotherapy approaches".

Reply 3: Abstracted expanded as suggested (Lines 28-32).

Comment 4: Please try to make different subtitles bold eg "PRECLINICAL DATA".

Reply 4: Added numbering and bold font to the subtitles as suggested.

Comment 5: Line 55: Please try to add such data and similar other work in a table format even as a supplementary material "PD-L1 in  $\geq 5\%$  of tumor cells was considered positive, and 6 of 10 ALK+ NSCLC" as it is important to the reader to know ALK+ NSCLC percentage in different PD-L1 expression levels.

Reply 5: Table 3 expands on these points as suggested.

Comment 6: Line 313: Please try to add current clinical trials in a table as this will be easier for the reader to get.

Reply 6: Table 4 with the referenced clinical trials has been added.

Comment 7: Figure 1: Please avoid abbreviations in the figure legend eg TIL, TKI, etc.

Reply 7: Edited as suggested.

#### Reviewer B

Comment 1: An author well summarized evidences of ALK+ NSCLC and immunotherapy approaches for patients with ALK+ NSCLC. TME may have a role in ALK+ NSCLC beyond PD-1/PD-L1 based immunotherapy. Because a lot of data were shown, the summarized tables may easily comprehensible.

Reply 1: I thank the reviewer for their time and comments on the manuscript.

Several tables have been added including Table 3: Select Studies of ALK+ NSCLC and PD-L1 expression and Table 4: Select current clinical trials for ALK+ NSCLC incorporating immunotherapy.

Comment 2: References 86-89 are probably cited from ClinicalTrials.gov. Please show the sauces.

Reply 2: These references have been reformatted for clarity.